1. SAT-220 Oral Contraceptives and Their Effect on the Evaluation of Cushing's Syndrome: A Case Report
- Author
-
Seng Kiong Tan, Timothy Peng Lim Quek, and Zhi Guang Ng
- Subjects
Pediatrics ,medicine.medical_specialty ,S syndrome ,business.industry ,Endocrinology, Diabetes and Metabolism ,Medicine ,Reproductive Endocrinology ,Reproductive Health throughout the Lifespan ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Background In the evaluation of Cushing’s syndrome (CS), oral contraceptives may lead to false-positive results by raising the serum levels of cortisol-binding globulin (CBG). Clinical Case An 18-year old Chinese lady presented with weight gain, irregular menses and hirsutism. History was unremarkable for hypothyroidism, hyperprolactinemia, eating disorders, and exogenous steroid use. On examination, she was overweight (body mass index (BMI) 26.9 kg/m2) with rounded facies, hirsutism and dorsal cervical fat pad. Initial biochemical tests showed high cortisol and ACTH levels: ACTH 66.6 pmol/L (RI 0-10.2 pmol/L) and random cortisol 958 nmol/L (RI: 240-618 nmol/L). She was referred to our department for evaluation of possible Cushing’s syndrome. Further history revealed that the patient was on a combined estrogen-progestin oral contraceptive pill (OCP). Confirmatory tests after cessation of the OCP for 6 weeks revealed normal 24-hr urinary cortisol levels (231 and 255 nmol/day, RI: 59-413 nmol/day) and a normal 1 mg dexamethasone suppression test (44 nmol/L after administration of 1 mg dexamethasone overnight, RI
- Published
- 2019